Gene Sequencing, Immune Response and Medicine

Takeda grows in gene therapies again with $2bn Code Bio deal

pharmaphorum

FEBRUARY 23, 2022

Takeda has forged another alliance as it continues a push into gene therapy, agreeing a deal worth up to $2 billion with Code Biotherapeutics for opt-in rights to four candidates for rare diseases. The deal is mostly back-loaded, with “double-digit million” dollars in upfront payment, research funding and milestone payments.

Gene Therapy

Gene Therapy Gene Gene Sequencing Immune Response

Medicago, GSK’s plant-made COVID jab clears phase 2

pharmaphorum

MAY 18, 2021

.” The interim phase 2 results show that two doses of the plant-derived jab stimulated neutralising antibody levels that are around 10 times higher than those in a panel of sera from patients recovering from COVID-19, with a similar response seen in adults and the elderly.

Vaccination

Vaccination Vaccine Immune Response Gene Sequencing

Clinical Research Informer

Takeda grows in gene therapies again with $2bn Code Bio deal

Medicago, GSK’s plant-made COVID jab clears phase 2

Webinars

Stay Connected